Skip to search formSkip to main contentSkip to account menu

SB 223412

Known as: SB-223412 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Quinolines

Narrower (1)

Talnetant

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412)
Review
2006
Review
2006
Defensive and pathological functions of the gastrointestinal NK3 receptor.
Review
2005
Review
2005
Talnetant GlaxoSmithKline.
Talnetant (SB-223412) is a selective, orally active NK3 antagonist based on 4-quinolinecarboxamide, and is under development by… 
2005
2005
Effect of neurokinins on canine prostate cell physiology
Sensory peptide neurotransmitters have been implicated as significant regulators of prostate growth. This study was designed to… 
Highly Cited
2002
Highly Cited
2002
Endogenous neurokinins facilitate synaptic transmission in guinea pig airway parasympathetic ganglia.
Neurokinin-containing nerve fibers were localized to guinea pig airway parasympathetic ganglia in control tissues but not in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)